PeptideStack
5.2kquestions
20kanswers
220users

At what point does vomiting on a GLP-1 agonist stop being a tolerability issue and become a clinical problem?

Asked 12 Nov 2024Modified 19 months agoViewed 32k times
56

I have vomited three times in the last ten days, always in the twenty-four to forty-eight hours after my injection, always in the morning, and each time I felt substantially better afterwards and got on with my day. My reading of the label is that this is an expected adverse effect and not an emergency.

What I cannot find anywhere is where the line is. Everything I read says either "nausea and vomiting are common and usually transient" or "seek medical attention for severe symptoms", and nothing tells me what separates the two in practice. "Severe" is doing an enormous amount of work in that sentence and I do not know what it means operationally.

What I would like is a set of criteria I could actually apply on a Sunday morning. Specifically:

  • How many episodes, over what interval, before this stops being expected?
  • What features of an episode matter independently of the count?
  • What would a clinician be looking for that I could look for myself?

I am not asking anyone to assess me. I am asking what the decision framework is, because at the moment I am using "do I feel like I can cope", which is not a criterion, it is a mood.

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

14 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

100 questions
hydration
hydration

Fluid intake when thirst and intake cues are both blunted: how much of the early scale drop is fluid, how dehydration confounds a renal panel, and…

14 questions
shareeditfollowflag
NN
askednine_point_nine45k13812 Nov 2024
8The distinction that matters is not how many times you vomited but whether you can replace what you lost. – amara_nwachukwu 5 months ago
7Morning-only vomiting in the 24-48 hour window is the textbook pattern, for what it is worth. – b_delacroix 3 months ago
add a comment

3 Answers

Accepted answer first, then by votes
147

Accepted answer

The operative variable is not episode count. It is whether your intake exceeds your losses, plus a short list of features that reclassify an episode regardless of how many there have been. One episode with the wrong features is a clinical problem; eight episodes over three weeks with maintained fluid intake and normal urine output is a tolerability problem. That is why the labels are vague: the count is genuinely not the discriminator.

The framework

Three questions, in order.

1. Can you keep fluid down? This is the whole question, and it is close to binary. If you can drink and retain a few hundred millilitres over an hour or two after an episode, you have a symptom. If every attempt at fluid comes back, you have a developing volume-depletion problem, and the clock on that is hours to a day, not weeks.

2. Is urine output maintained? The cheapest objective measurement available to you. Passing urine at roughly normal frequency, pale to mid-yellow, is reassuring. Not having passed urine in eight to twelve hours, or passing a very small volume of dark concentrated urine, is not. Note that this is more informative than thirst, because thirst signalling is itself altered on this class and several people report drinking less without noticing.

3. Does the episode have any of the reclassifying features? Listed below. These override the count entirely.

Features that make a single episode significant

  • Abdominal pain that is severe, constant, or radiates to the back or right shoulder. Pancreatitis classically radiates through to the back; biliary pain to the right shoulder tip or between the shoulder blades. Both occur on this class. Pain out of proportion to the vomiting is the pattern to notice.
  • Fever, rigors or jaundice. Suggests cholecystitis or cholangitis rather than a drug effect.
  • Vomiting that begins abruptly after a period of stability at an unchanged dose. The drug did not change; something else did.
  • Vomiting of blood, or material that looks like coffee grounds. Emergency, without qualification. Repeated forceful vomiting can also cause an oesophageal mucosal tear.
  • Complete absence of bowel movements plus distension plus vomiting. That combination raises obstruction or ileus, both of which have been reported on this class, and it is managed very differently from nausea.
  • Faecal odour to the vomitus, or vomiting of material eaten more than about eight hours previously. Retention or obstruction rather than emesis.
  • Confusion, marked dizziness on standing, palpitations, or inability to stand. Circulatory consequences of volume depletion.
  • Reduced urine output as above.
  • Any of this in someone taking a diuretic, an ACE inhibitor, an angiotensin receptor blocker, an SGLT2 inhibitor, a sulfonylurea, insulin, lithium, metformin or an NSAID. Those drugs change the arithmetic substantially, which is the subject of the answer below.

What would a clinician look at

Beyond examination: postural blood pressure, capillary refill, mucous membranes, and a basic panel comprising urea and creatinine with electrolytes, sometimes with bicarbonate, chloride and glucose. Also lipase or amylase if pancreatitis is on the list, liver enzymes and bilirubin if biliary disease is, and imaging if either is genuinely suspected. Nothing you can do at home replaces that. What you can do at home is track the three questions above, which is what determines whether the panel is warranted.

Where your own pattern sits

Three episodes in ten days, all in the 24-48 hour post-dose window, all followed by improvement, with normal function in between, is the classic phase-locked pattern. That is the expected profile. The specific things I would watch, given that pattern:

  • Whether the count is rising. Three in ten days is a symptom. Three per week rising to daily is a trajectory, and trajectories are more informative than snapshots.
  • Whether it persists into the second half of the dosing week. Loss of the phase-locking is the single most useful sign that something has changed.
  • Your total fluid intake, measured rather than estimated, for a week. Most people are surprised, and the direction of the surprise is always the same.
  • Whether it survives the next four weeks at the current dose. If you are within a fortnight of a dose step it will very likely improve on its own; if you have been at this dose for two months it will not.

Worth naming the failure mode this framework exists to prevent. It is not people ignoring dramatic symptoms; it is people normalising a slow slide. Vomiting twice a week for two months, drinking a bit less each week because drinking makes it worse, feeling increasingly tired and attributing that to the deficit, and arriving at a genuine acute kidney injury without ever having had a day that felt like an emergency. Every step in that sequence feels tolerable. The endpoint is not. That is why the criterion should be an objective one you check on a schedule rather than a judgement you make when you feel bad.

edited 25 Dec 2024 by dmitri_savchuk — corrected a unit error in the worked example

shareimprove this answerflag
DS
answered · accepteddmitri_savchuk17k1621 Dec 2024
Urine output over thirst is the correct emphasis. Thirst is unreliable on these drugs and almost nobody is told that. – e_dziedzic 2 months ago
8The slow-slide description is exactly what happened to me. Nine weeks, no single bad day, eGFR of 41 at the end of it. – nine_point_nine 15 days ago
7Vomiting food from the previous evening is a genuinely different sign and I had no idea it meant something separate. – claudia_ferrante 5 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
84

Adding the drug-interaction layer, because it is the difference between vomiting for a week being unpleasant and vomiting for a week putting someone in hospital, and it is the part most often missing from the conversation.

Volume depletion reduces renal perfusion. Several very common medications either depend on renal perfusion for safety or become dangerous when renal clearance falls. Combining them with a period of poor intake is what turns a tolerability episode into an admission.

Medication classWhat volume depletion doesConsequence
ACE inhibitors, angiotensin receptor blockersBlock the compensatory efferent arteriolar constriction that maintains glomerular filtration when perfusion fallsSharper fall in filtration rate than volume depletion alone would cause
NSAIDs (including over-the-counter ibuprofen)Block the prostaglandin-mediated afferent vasodilation that is the other half of the same compensationThe combination of an ACE inhibitor, a diuretic and an NSAID during volume depletion is a well-described route to acute kidney injury
DiureticsAdd renal losses to gastrointestinal onesCompounds both volume and electrolyte depletion
SGLT2 inhibitorsOsmotic diuresis continues regardless of intake; ketogenesis rises with low carbohydrate intakeVolume depletion plus a real risk of euglycaemic ketoacidosis during illness or fasting
MetforminRenally cleared; accumulates as filtration fallsLactic acidosis risk, which is why sick-day guidance exists for it
Sulfonylureas, insulinDose was set against an intake that has now stoppedHypoglycaemia, potentially severe, and this is the acute risk in anyone with diabetes
LithiumReabsorbed in proportion to sodium; clearance falls with volume depletionToxicity at an unchanged dose. Narrow therapeutic index and a genuinely dangerous interaction
Digoxin, and other narrow-index renally cleared drugsReduced clearanceToxicity at an unchanged dose
Oral contraceptives and other oral drugs, during vomitingAbsorption unreliableLoss of efficacy, sometimes unnoticed

The practical point: "sick-day rules" exist for several of these classes and are ordinarily explained to people with diabetes and to people on renin-angiotensin blockade. They are seldom explained to someone starting a GLP-1 agonist, even though a drug whose principal adverse effects are vomiting and reduced oral intake is precisely a sick-day generator. If you take anything in the table above, the conversation to have with a clinician is not "is vomiting normal" but "what should I do with these other medications during a bad few days", and that conversation is best had before it happens rather than during.

Two additional notes. First, gastric retention makes the absorption of any oral medication less predictable, so the effect on other drugs is not only about clearance. Second, this is one of the few areas where the pharmacovigilance signal is unambiguous: acute kidney injury reports on this class cluster heavily in people with vomiting or diarrhoea, which is to say the renal signal appears to be substantially a volume-depletion signal rather than a direct nephrotoxic one. That is reassuring about the mechanism and not at all reassuring about the consequence.

shareimprove this answerflag
BC
answeredbea_castellanos47k13810 Dec 2024
4The lithium interaction should be on the front page of every patient information leaflet for this class. – Dr_Signe_Baldursdottir 2 months ago
5Sick-day rules for a drug that causes sick days is such an obvious gap that it is strange it persists. – mz_4113 4 months ago
add a comment
41

A narrower point on the phase-locking that the accepted answer treats as reassuring, because it has a specific failure mode.

The 24-48 hour post-dose window is where emetic episodes cluster, and for a weekly agent that is one or two days out of seven. The reassuring reading is that you have five good days. The less reassuring reading is that many people use those five days to catch up and the catching up is incomplete in a specific dimension.

What gets replaced during the good days: fluid, mostly, because thirst and habit both work in that direction. What does not get replaced reliably:

  • Protein. Two days of near-zero intake per week is a 28% reduction in weekly protein availability if the other five days are merely adequate rather than compensatory. Nobody eats double protein on Thursday to make up for Monday.
  • Electrolytes, particularly potassium and magnesium, which come predominantly from food rather than from water and which are lost in gastric contents.
  • Micronutrients, on the same logic.

So the weekly cycle can be simultaneously tolerable in the sense that matters acutely and cumulatively depleting in a way that does not announce itself. The presentation of that, months later, is fatigue, cramps, hair shedding, poor training performance and a disproportionate loss of lean mass, all of which get attributed to the energy deficit because the vomiting was never severe enough to seem causal.

The measurement that resolves it is unglamorous: track intake across a full dosing week rather than on a typical day. A food diary that starts on a good day and runs for three days will systematically overestimate your weekly intake by a wide margin, and that is the most common form of self-deception in this whole area. Seven consecutive days, including the bad ones, or the number means nothing.

shareimprove this answerflag
KS
answeredk_szabo45k3829 Nov 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.